I am second year resident of general medicine i have a presentation on pulmonary hypertension with venous and pulmonary thromboembolism kindly give me detailed description in ppt format with updated guidelines
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
"pulmonary hypertension" AND guidelines
Searching PubMed
"pulmonary embolism" AND "venous thromboembolism" AND guidelines
Reading File
Reading File
Reading Article
Searching Images
pulmonary hypertension classification pathophysiology diagram
Reading File
Reading File
Searching Images
pulmonary embolism CT angiography diagnosis Wells score
Searching the Web
2026 AHA ACC pulmonary embolism guideline key recommendations risk stratification treatment
Reading Web Page
2026 AHA ACC PE guideline risk categories treatment recommendations anticoagulation thrombolysis
Finding Sources
Searching Images
deep vein thrombosis DVT ultrasound Virchow triad pathophysiology
Running Command
Writing File
Running Command
Running Command
Your presentation is ready! Here's the download link:
PH VTE PE Presentation 2026
Presentation · PPTX
What's inside (20 slides, dark navy/teal/gold theme)
| # | Slide Title |
|---|---|
| 1 | Title Slide – Pulmonary Hypertension, VTE & PE – May 2026 |
| 2 | Presentation Outline – 10-section visual index |
| 3 | Section Divider – Part 1: Pulmonary Hypertension |
| 4 | PH: Definition & WHO Classification – All 5 groups with updated mPAP >20 mmHg definition (ESC/ERS 2022) |
| 5 | PH Pathophysiology – Endothelial dysfunction, vascular remodeling, RV failure; with medical diagram |
| 6 | PH: Clinical Features & Diagnosis – Symptoms, signs, 9-investigation workup (RHC as gold standard) |
| 7 | PAH: Targeted Therapy – Three pathway pharmacology table (ERA / PDE5i-sGC / Prostacyclin) |
| 8 | Section Divider – Part 2: VTE & PE |
| 9 | DVT: Virchow's Triad & Risk Factors – Three-column visual layout |
| 10 | DVT: Wells Score & Management – Scoring table with duplex ultrasound image; DOAC guidance |
| 11 | PE Pathophysiology & Epidemiology – 6-step cascade + CTPA image (bilateral filling defects) |
| 12 | 2026 AHA/ACC PE Clinical Categories A–E ⭐ New system replacing massive/submassive/low-risk |
| 13 | Wells PE Score + PERC Rule – Side-by-side scoring tables with interpretation |
| 14 | PE Management (2026 AHA/ACC) – Category-stratified treatment; IVC filter Class III Harm |
| 15 | Anticoagulant Drug Comparison Table – 7 agents; doses, reversal agents, special considerations |
| 16 | CTEPH – Pathogenesis, V/Q diagnosis, surgical PTE, BPA, riociguat |
| 17 | Duration of Anticoagulation – 7 clinical scenarios; half-dose DOAC evidence (EINSTEIN CHOICE/AMPLIFY-EXT) |
| 18 | ESC/ERS 4-Strata Risk Stratification for PAH – Low/Int-Low/Int-High/High + treatment at each level |
| 19 | VTE in Special Populations – Pregnancy, Cancer, Renal impairment |
| 20 | Key Takeaways + References – 7 board-ready bullet points |
Key guideline highlights incorporated:
- 2026 AHA/ACC PE Guideline (Creager et al., Circulation / JACC) – first ever dedicated PE guideline from AHA/ACC; introduces A–E category system; DOACs Class I; IVC filter Class III Harm
- ESC/ERS 2022 PH Guidelines – updated mPAP threshold, 4-strata risk, upfront combination therapy
- 2025 ESVM VTE Interventional Guidelines
- Murray & Nadel's and Fishman's Pulmonary Diseases as primary textbook sources
This is a shared conversation. Sign in to Orris to start your own chat.